Nanoparticles Disguised as Red Blood Cells Deliver Cancer-Fighting Drugs
Researchers at the University of California, San Diego have developed a novel method of disguising nanoparticles as red blood cells, enabling the resulting nanoparticles to evade the body's immune system and deliver cancer-fighting drugs straight to a tumor. The method involves collecting the membrane from a red blood cell and wrapping it like a powerful camouflaging cloak around a biodegradable polymer nanoparticle stuffed with a cocktail of small molecule drugs.
"This is the first work that combines the natural cell membrane with a synthetic nanoparticle for drug delivery applications," said Dr. Liangfang Zhang. "This nanoparticle platform will have little risk of immune response." Zhang and his collaborators published the results of their studies in the Proceedings of the National Academy of Sciences.
Researchers have been working for years on developing drug delivery systems that mimic the body's natural behavior for more effective drug delivery. That means creating vehicles such as nanoparticles that can live and circulate in the body for extended periods without being attacked by the immune system. Red blood cells live in the body for up to 180 days and, as such, are nature's long-circulation delivery vehicle.
Stealth nanoparticles are already used successfully in clinical cancer treatment to deliver chemotherapy drugs. They are coated in a synthetic material such as polyethylene glycol that creates a protection layer to suppress the immune system so that the nanoparticle has time to deliver its payload. Zhang said today's stealth nanoparticle drug delivery vehicles can circulate in the body for hours compared to the minutes a nanoparticle might survive without this special coating. But in Zhang's study, nanoparticles coated in the membranes of red blood cells circulated in the bodies of lab mice for nearly two days.
Using the body's own red blood cells marks a significant shift in focus and a major breakthrough in the field of personalized drug delivery research. Trying to mimic the most important properties of a red blood cell in a synthetic coating requires an in-depth biological understanding of how all the proteins and lipids function on the surface of a cell. Instead, Zhang's team is just taking the whole surface membrane from an actual red blood cell.
"We approached this problem from an engineering point of view and bypassed all of this fundamental biology," said Zhang. "If the red blood cell has such a feature and we know that it has something to do with the membrane—although we don't fully understand exactly what is going on at the protein level—we just take the whole membrane. You put the cloak on the nanoparticle, and the nanoparticle looks like a red blood cell."
Using nanoparticles to deliver drugs also reduces the hours it takes to slowly drip chemotherapy drug solutions through an intravenous line to just a few minutes for a single injection of nanoparticle drugs. This significantly improves the patient's experience and compliance with the therapeutic plan. This particular breakthrough could lead to more personalized drug delivery wherein a small sample of a patient's own blood could produce enough of the essential membrane to disguise the nanoparticle, reducing the risk of immune response to almost nothing.
Dr. Zhang said one of the next steps is to develop an approach for large-scale manufacturing of these biomimetic nanoparticles for clinical use, a project already underway. The investigators will also add a targeting molecule to the membrane that will enable the particle to seek and bind to cancer cells, and integrate the team's technology for loading drugs into the nanoparticle core so that multiple drugs can be delivered at the same time.
This work, which is detailed in a paper titled, "Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic platform," was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. An abstract of this paper is available at the journal's website.
Source: National Cancer Institute /...
The Institute of Nanotechnology puts significant effort into ensuring that the information provided on its news pages is accurate and up-to-date. However, we cannot guarantee absolute accuracy. Consequently, the Institute of Nanotechnology disclaims any and all responsibility for inaccuracy, omission or any kind of deficiency in relation to the news items and articles hosted herein.
- 04 March 2014NanoCelluComp presents final results at JEC Europe 2014
- 17 February 2014Researchers Hijack Cancer Migration Mechanism to “Move” Brain Tumours
- 12 February 2014Fingerprinting meningitis with lasers
- 06 February 2014European Innovation Convention 2014
- 30 January 2014NanoSafety Cluster Newsletter No.2 - Out Now
- View All